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A B S T R A C T
The year 2020 will be remembered by a never before seen, at least by our generation, global pandemic of COVID-
19. While a desperate search for effective vaccines or drug therapies is on the run, nutritional strategies to
promote immunity against SARS-CoV-2, are being discussed. Certain fermented foods and probiotics may deliver
viable microbes with the potential to promote gut immunity. Prebiotics, on their side, may enhance gut im-
munity by selectively stimulating certain resident microbes in the gut. Different levels of evidence support the
use of fermented foods, probiotics and prebiotics to promote gut and lungs immunity. Without being a promise
of efficacy against COVID-19, incorporating them into the diet may help to low down gut inflammation and to
enhance mucosal immunity, to possibly better face the infection by contributing to diminishing the severity or
the duration of infection episodes.
1. Introduction
An outbreak of coronavirus disease (COVID-19), caused by severe
acute respiratory syndrome (SARS-CoV-2), has rapidly spread from
China to almost all over the world affecting over 13,200,000 people
across 199 countries by early July 2020. By that time, more than
577,000 people were lost to the virus (John Hopkins University, 2020).
The SARS-CoV-2 coronavirus is part of a family of viruses, known as
coronaviruses, common in nature, with many potential natural primary,
intermediate, and final hosts (Wang et al., 2020). These viruses cause
respiratory infections, such as the severe acute respiratory syndrome -
SARS (whose agent is SARS-CoV) and the Middle East respiratory
syndrome - MERS (whose agent is MERS-CoV). In the past, human
coronaviruses (HCoVs) have been considered to be relatively harmless
respiratory pathogens till the outbreaks SARS and MERS (Yin &
Wunderink, 2018). Due to the fact that SARS-CoV-2 is 96% identical at
the whole-genome level to a bat coronavirus, the domestication and/or
consumption of wildlife animal was pointed as the possible origin for
the disease (Wu et al., 2020).
COVID-19 has emerged as a multifaceted, multi-system and multi-
organ disorder ranging from non-specific flulike symptoms, to pneu-
monia, acute respiratory distress syndrome (ARDS), multiple organ
failure and death (Baud et al., 2020; Chen et al., 2020; Infusino et al.,
2020). Other described clinical findings are: septic shock, metabolic
acidosis and coagulation dysfunction (Infusino et al., 2020). For-
tunately, most patients have mild symptoms and present good prog-
nosis (Chen et al., 2020).
Coronavirus entry is mediated by the viral spike (S) glycoprotein.
Then, SARS-CoV-2 binds to the angiotensin-converting enzyme 2
(ACE2) (Bosch et al., 2003). Binding to ACE2 allows the virus to invade
cells in the oropharyngeal epithelia and the development of lung injury
and hyperinflammation (Rivellese & Prediletto, 2020; Xu, Zhong, et al.,
2020). At the pulmonary level ACE2 is expressed on the epithelial cells
of alveoli, trachea, bronchi, bronchial serous glands, alveolar mono-
cytes and macrophages (Yin & Wunderink, 2018). It has been postu-
lated that different concentrations and/or activation of ACE2 at the
pulmonary level can be a reason for higher incidence of COVID-19 in
adults, compared to children (Fanos et al., 2020).
Interestingly, Zhang et al. (2020) showed that ACE2 is not only
highly expressed in the lung AT2 cells, esophagus upper and stratified
epithelial cells but also in absorptive enterocytes from ileum and colon.
These results indicated along with respiratory systems, that the diges-
tive system is a potential route for 2019-nCov infection.
In this way, the ACE2 has a specific function in intestinal tract,
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regulating intestinal amino acid homeostasis, expression of anti-
microbial peptides, and the ecology of the gut microbiome. In addi-
tional, ACE2-dependent changes in epithelial immunity and the gut
microbiota can be directly regulated by the dietary amino acid tryp-
tophan. Then, ACE2 is key regulator of dietary amino acid homeostasis,
innate immunity, gut microbial ecology, and transmissible suscept-
ibility to colitis (Hashimoto et al., 2012).
The role of non-pharmacological substances such as probiotics and
nutraceuticals can be an interesting option considering the long time
necessary to find, evaluate and produce drugs that are able to interfere
with SARS-CoV-2 pathway (Infusino et al., 2020). This review aims to
discuss the possible correlation between COVID-19 infection and mi-
crobiota. In addition, we show scientific evidence on the possible role of
consumption of fermented foods, as well as probiotics and prebiotics in
promoting mucosal immunity to better face a possible infection.
2. COVID-19 affecting intestinal tract
The most common symptoms of COVID-19 at the onset of illness are
fever, cough, fatigue, myalgia, dyspnea, headache, stomachache, pains
in the rib cage, loss of taste and smell, skin problems like hives or chills
on the toes, neurological problems and gastrointestinal (GI) symptoms,
such as diarrhea and nausea (Huang et al., 2020).
Tissue tropism of coronavirus in the intestinal tract was first de-
scribed by Leung et al. (2003) for the SARS-CoV responsible for the
SARS outbreak in Hong Kong in March 2003. It was reported the pre-
sence of active viral replication in the small and large intestine of the
patients, and also evidence of virus accumulation inside endoplasmic
reticulum of enterocytes (Leung et al., 2003).
A lot of evidence shows that human-to-human transmission occurs
in close contact, mainly transmitted through respiratory droplets,
aerosols and direct contact. Many findings suggest that the intestine
could also have a relevant role both in the COVID-19 evolution and as a
possible route of infection, so an oral fecal route has also been eval-
uated (Infusino et al., 2020; Li et al., 2020). Viral RNA from SARS-CoV-
2 can be found in stools of previously infected patient, even after ne-
gativization in the exam from the respiratory tract (Infusino et al.,
2020). According to Zhang et al. (2020) enteric symptom of diarrhea
would be associated with the invaded ACE2-expressing enterocytes.
Even so more studies are needed to confirm this hypothesis.
Jin et al. (2020) evaluated patients with COVID-19 in the Zhejiang
province. 11.4% of these patients (average age of 46.14 years) pre-
sented with at least one GI symptom (nausea, vomiting or diarrhea),
and GI symptoms were recorded on admission, precluding the influence
of other medical therapy and external factors. Li et al. (2020) evaluated
95 cases with SARS-CoV-2 caused coronavirus disease 2019. Among
them, 58 cases exhibited GI symptoms (diarrhea, anorexia, and nausea)
of which 11.6% occurred on admission and 49.5% developed during
hospitalization. However, the authors did not correlated the drug ad-
ministration and GI symptoms. They found presence of SARS-CoV-2 in
faecal samples in 52.4% of patients and SARS-CoV-2 RNA was detected
in oesophagus, stomach, duodenum, and rectum specimens for both
two severe patients. In addition, patients with GI symptoms revealing
oesophagus bleeding with erosions and ulcers.
The more detailed information on the characteristics of COVID-19 is
found for adult and elder people, but for children is still scarce. A recent
publication showed five children with non-respiratory symptoms as the
first manifestation were hospitalized from the emergency department at
the Wuhan Children's Hospital and were later confirmed to have
COVID-19. Interestingly, that two of these patients had acute gastro-
enteritis symptoms (Cai et al., 2020).
Viral replication in the intestine determines an exponential increase
in the viral load in the digestive mucosa, leading to a loss of barrier
integrity and a strong production of cytokines (Infusino et al., 2020).
3. A shrinking microbiota: An immunocompromised individual
The term human microbiota refers to the set of microorganisms that
we host as human beings. We are colonized on the outside (skin, eyes)
and inside (vagina, oral, respiratory, and intestinal tract mucosa) by a
large number of bacteria (Bacteroides, Clostridium, Faecalibacterium,
Eubacterium, Ruminococcus, Peptococcus, Peptostreptococcus, and
Bifidobacterium), fungi (Aspergillus, Candida, Debaryomyces, Malassezia,
Penicillium, Pichia, and Saccharomyces), protozoa (Cryptosporidium spp.,
Giardia intestinalis, Entamoeba histolytica), archaea (Methanobacterium
and Woesearchaeota), and even viruses (Enterovirus, Rotavirus,
Norovirus), which are essential for life (Thursby & Juge, 2017). In
particular, the intestinal microbiota, formerly known as “intestinal
flora”, is the set of microbes, mainly bacteria, that colonize the small
and large intestine, being the colon the portion of the intestine that
hosts the greatest amount and diversity of bacteria. These intestinal
bacteria remain active and functional by being feed an essential, but
often disregarded, part of the food: fibers. Through the intestinal fer-
mentation of the food fiber, gut microbes manage to reproduce, to cover
our intestine mucosa and to exert numerous functions. Some of these
are the complementary digestion of the food, the synthesis of anti-in-
flammatory substances such as butyric acid, the reinforcement of the
intestinal epithelial barrier, the prevention of infections and, perhaps
their most important function, the modulation of the gut associated
lymphoid tissue to promote and modulate gut and systemic immunity.
Most of the immune cells, the army that keep alert to possible infections
from undesirable bacteria and viruses, are housed in the intestine. The
interaction of the microbiota with the immune cells train naïve cells, so
that they can fulfil their role of defense against external challenges
(Rooks & Garrett, 2016). Additionally, the gut is related to the brain
through a two-way communication route, mediated by intestinal neu-
rons that reach the brain and numerous effector molecules (neuro-
transmitters, cytokines) that travel in both directions through what is
called the gut-brain axis. It is curious, but over 90% of serotonin, one of
the neurotransmitters responsible for regulating mood, social behavior,
appetite, digestion or sleep, is produced in the gut (Cryan et al., 2019).
The acquisition of microbiota is a dynamic process that begins at
birth and reaches maturity in the first 2–3years of life. This is a period
where a window of opportunities is deployed for the establishment of
an abundant, diverse, and functional microbiota, which will properly
educate the immune system to develop the oral tolerance later in life.
Babies born full term and vaginal delivery, prolonged breastfeeding and
the interaction with the family environment have been reported to
promote the establishment of a functional intestinal microbiota (Milani
et al., 2017), while factors such as premature delivery, cesarean section,
insufficient breastfeeding and administration of antibiotics, or their
combinations, are associated with ineffective microbiota development
and immune disorders or inflammatory-based diseases during infancy
and childhood, such as overweight, obesity, allergies, inflammatory
bowel disease, or GI and respiratory infections (Tamburini et al., 2016).
This combination of modern health practices and life-style has led to a
gradual loss in microbial abundance and diversity in the gut, considered
a microbe in constriction (Moeller, 2017), leading to a vulnerability of
the “industrialized microbiota” (Sonnenburg & Sonnenburg, 2019).
In this context, diet, age, stress, and diseases can cause increases or
decreases in relative abundance and diversity of bacterial species in GI.
The persistent imbalance of gut's microbial community, named dys-
biosis, relates to some intestinal or extra intestinal diseases (Belizário &
Faintuch, 2018). Being microbial diversity an indicator of potential
microbiota endurance and resilience capacity, evidence for the asso-
ciation of the composition of the pharyngeal microbiota with SARS-
CoV-2 infection was reported (Budding et al., 2020). These authors
observed age-dependency of the pharyngeal microbiota composition,
being less diverse in older people. This less-diverse profile along age
may contribute to explain the enhanced susceptibility of the elderly to
COVID-19. However, further studies are needed to support this
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hypothesis.
Dysbiosis microbiome may create an inflammatory environment
that the coronavirus can exploit. Gut-related inflammatory proteins,
cytokines, are amplified by more cytokines when coronavirus hits. The
combined inflammation may ignite a “cytokine storm”—a runaway
immune reaction that can cause more damage than the virus itself,
including multiorgan injury (Yang et al., 2020).
A recent Chinese study identified marker bacterial related with
COVID-19 susceptibility. Based on the COVID-19 patient data, they
constructed a blood proteomic risk score (PRS) for the prediction of
COVID-19 progression to clinically severe phase. Then, Ruminococcus
gnavus was positively correlated with inflammation, while Clostridia
spp. was negatively correlated. They also found a strong association
between these bacteria, the PRS, and COVID-19 severity, but only in
older age groups. In additional, they looked at a subgroup of 301 non-
infected people over a three-year period. Intriguingly, they found that
microbiome alterations occurred before the change was reflected by the
PRS, making it plausible that dysbiosis causes the protein alterations
and not the other way around (Gou et al., 2020).
Then, dietary strategies for the promotion of the gut microbiota, and
thus the strengthening of the immune system associated with the gut,
include increased consumption of fiber and prebiotics (Holscher, 2017),
and incorporating fermented foods (Marco et al., 2017), and probiotics
(Zmora et al., 2019) into the diet. The provision of viable micro-
organisms to the gut achieved by probiotics and certain fermented
foods carrying viable microbes means that, during the time they remain
in the gut environment, they may perform some of the functions nor-
mally carried out by native microbes, in a context of often impoverished
microbiota. Probiotics, prebiotics and fermented foods carrying viable
microorganisms may be a booster to the activity of the microbiota and
the intestinal immunity (Ashraf & Shah, 2014).
4. Fermented foods and probiotics
Fermented foods are those foods produced by microbial action and
their enzymes under controlled conditions. Fermentation prolongs the
shelf life of the originating food, improves its digestibility, making
many of its nutrients more digestible. Fermentation also produces a
number of metabolites and microorganisms with potential health ef-
fects (Tamang et al., 2020). Fermented foods are a very diverse family
of foods, which differ in their nutritional value and microbiological
composition, as well as in their potential beneficial effects for health, or
those already established through well designed clinical efficacy stu-
dies. Some fermented foods do not contain microorganisms (wine,
Fig. 1. Dysbiosis process, a perturbation of the microbial community, it may decrease the microbiota diversity, shift the its composition and, consequently, facilitate
the invasion and viral replication. It might create an inflammatory environment explored by SARS-CoV-2. Pathogens microbes and virus contribute toward an
intestinal and lung barrier dysfunction, with liberations of pro-inflammatory cytokines, promoting a “cytokine storm”. Unhealthy diet might reduce the phagocytic
activity and modulation of the production of immunoglobulins/antibodies that mediate host defense, lowering the elimination intracellular pathogens and the
immune response. ACE2, angiotensin-converting enzyme 2; L-cell, enteroendocrine L-cell; M cell, microfold cell; SARS-CoV-2, severe acute respiratory syndrome.
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beer), or the microorganisms are not viable (sourdough bread, pas-
teurized sauerkraut), while others may contain living microorganisms,
such as yoghurt, yoghurt with probiotics, kefir or kombucha. On the
other hand, in some of them, the microbiological composition is known
in advance (yoghurt, yoghurt with probiotics), while in others it is not
possible to know which microorganisms are present in a given batch
(kefir, kombucha, sauerkraut).
Probiotics are live microorganisms that, when administered in
adequate amounts, confer a health benefit on the host (Hill et al.,
2014), whereas prebiotics are substrates that are selectively utilized by
host microorganisms conferring a health benefit, including carbohy-
drate and non-carbohydrate substances (Gibson et al., 2017). Probiotics
can be found in food supplements or in foods, fermented (yoghurt,
fermented oats) or not (fruit juices), being yoghurt the most widely
used food as a vehicle for probiotics (Syngai et al., 2016). The most
widely used probiotics in supplements belong to the genera Lactoba-
cillus, Bifidobacterium, Saccharomyces, and Bacillus, while Lactobacillus
and Bifidobacterium are almost exclusively used in foods. The char-
acteristics that a probiotic strain must display are: 1) identity (genera,
species, and strain denomination); 2) to be viable in the supplement or
food at the moment of intake; and 3) a human efficacy study that de-
monstrates its beneficial effects. There is scientific evidence about the
ability of probiotics to promote gut immunity (Sánchez et al., 2017)
and, for the moment, a modest evidence of their role in reducing the
severity of acute upper respiratory tract infections (AURTI) (Hao et al.,
2015). The use of specific probiotics was recently proposed as a way to
contribute to flatten the curve of coronavirus disease (Baud et al.,
2020).
Fermented foods are not a synonym of probiotics, and vice versa.
Not all fermented food can be regarded as probiotics and not all pro-
biotics are delivered through fermented foods. For example, kefir mi-
crobiota is dependent on its origin (Gao & Li, 2016). In addition, the
microbiota of kefir changes along the successive subcultivations of the
kefir grains used to produce this fermented food (Gao et al., 2015).
Then, technically products with undefined microbiota such as kefir,
sauerkraut or kombucha, do not qualify as probiotics (Reid et al.,
2019), however these fermented foods can have potential beneficial
effects due to their content of viable microorganisms (Rosa et al., 2017).
In case of yoghurt (milk fermented by Streptococcus thermophilus and
Lactobacillus delbrueckii subsp. bulgaricus) added of selected probiotic
Fig. 2. Main mechanisms of action of fermented foods, probiotics, and prebiotics. Prebiotics are selectively utilized by the commensal microbiota, releasing me-
tabolites like short chain fatty acids (SCFA), promoting leukocyte recruitment to the site of infection, as well as their activation. The SARS- CoV-2 binds to the ACE2.
Fermented foods and probiotics strains may also increase the phagocytic activity and modulate the production of immunoglobulins/antibodies mediate host defense
by eliminating intracellular pathogens, improving the immune response, intestinal microbiota has a marked influence on metabolic pathways within alveolar
macrophages, which correlates with an altered cellular responsiveness, promoting the microbiota modulation has a marked influence on metabolic pathways within
alveolar macrophages, nutritional interventions of omega-3 polyunsaturated fatty acids, selenium, zinc, iron, vitamins A, B2, B3, B6, C, D, and E to combat viral
infections. ACE2, angiotensin-converting enzyme 2; L-cell, enteroendocrine L-cell; M cell, microfold cell; SARS-CoV-2, severe acute respiratory syndrome.
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cultures (often belonging to species such Bifidobacterium lactis or Lac-
ticaseibacillus casei, Lacticaseibacillus paracasei, Lacticaseibacillus rham-
nosus, formerly known as Lactobacillus casei, Lactobacillus paracasei, and
Lactobacillus rhamnosus), the terms fermented foods and probiotics both
apply. It is worth noting that the genera Lactobacillus has been recently
re-classified and some names changed (Zheng et al., 2020). Another
product where both terminologies fit is the product obtained by the
mixture of oat fermented with the probiotic strains Lactiplantibacillus
plantarum 299v (formerly known as Lactobacillus plantarum 299v) and
fruit pulps (Molin, 2001), that can be found in many Nordic countries.
An increasing interest in fermented foods was witnessed over the last
several years (Taylor et al., 2020). Profiting the spare time while being
locked down during the quarantine held in many countries due to the
COVID-19 pandemic, many people improved their skills or discovered
food fermentation as a way of ingesting live microbes with the potential
of promoting gut immunity to better face a possible infection. In a
context of impoverished and threatened intestinal microbiota, the
consumption of home-made fermented foods (yoghurt, kefir, sauerk-
raut, kombucha) or the incorporation into the diet of commercial pro-
ducts containing probiotics and prebiotics, as food or food supplements,
is part of a comprehensive nutritional strategy to enhance the function
of the gut microbiota, to promote mucosal immunity and potentially
upper respiratory tract immunity, to be potentially better prepared to
face viral or bacterial infections caused by respiratory syndromes.
It is worth mentioning the Zhejiang experience in the management
of COVID-19. The National Clinical Research Center for Infectious
Diseases, the First Affiliated Hospital of Zhejiang University School of
Medicine, is the primary medical care center for COVID-19 in the
Province of Zhejiang. An expert consensus protocol was developed by
the National Health Commission and National Administration of
Traditional Chinese Medicine, focused on “four-anti and two-balance”
strategies for clinical practice in case of infected patients. This protocol
included antivirus, anti-shock, anti-hypoxemia, anti-secondary infec-
tion, and maintaining of water, electrolyte, acid base balance and in-
testinal microbial balance through nutritional support and application
of prebiotics or probiotics to regulate the balance of intestinal micro-
biota and to reduce the risk of secondary infection due to bacterial
translocation (Xu, Cai, et al., 2020).
5. Probiotics in the prevention of respiratory disease
Researchers from several countries have been working on the search
for effective treatment against COVID-19 and for the development of a
vaccine against the SARS-CoV-2 virus. However, there are no drugs
approved by the Food and Drug Administration (FDA) so far, and a
vaccine will not be available in the near future (Baud et al., 2020;
COVID-19 Treatment Guidelines Panel, 2020). For the moment, a
clinical trial is being performed on the effect of L. rhamnosus GG on the
microbiome of household contacts exposed to COVID-19 (U.S. National
Library of Medicine, Clinical Trial gov Identifier NCT04399252, 2020).
Other ongoing studies using probiotics to prevent or treat COVID-19 are
“Evaluation of the probiotic Lactobacillus coryniformis K8 on COVID-19
prevention in healthcare workers” (U.S. National Library of Medicine,
Clinical Trial gov Identifier NCT04366180, 2020); “Oxygen–ozone as
adjuvant treatment in early control of COVID-19 Progression and
modulation of the gut microbial flora (Probiozovid)” (U.S. National
Library of Medicine, ClinicalTrials.gov Identifier: ClinicalTrials.gov
Identifier: NCT04366089, 2020); and “Bacteriotherapy in the treatment
of COVID-19 (BACT-ovid)” (U.S. National Library of Medicine,
ClinicalTrials.gov Identifier: NCT04368351, 2020).
Some comorbidities, such as obesity and hypertension may increase
the risk of a worse prognosis for COVID-19 and require mechanical
breathing. In overweight and obese patients, although there is a high
food consumption, frequently is observed a deficiency in some nutrients
due to unbalanced diet. Zhang and Liu (2020), pointed the importance
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response against RNA viral infections, such as SARS-CoV-2. Their re-
view emphasized the contribution of vitamins A, B2, B3, B6, C, D, E,
omega-3 polyunsaturated fatty acids, selenium, zinc, and iron to
combat viral infections. Diet fiber might also be beneficial in this
context because diets with high fiber content (30 g/d) are associated
with lower levels of inflammatory markers (King et al., 2007). Infusino
et al. (2020) emphasized also the importance of polyphenols (flavo-
noids, phenolic acids, stilbenes, lignans) to provide health benefits
maintaining a proper redox homeostasis.
The excess body weight per se can cause a mechanical difficulty to
the lung ventilation process, aggravated by the decrease in muscle
strength of the diaphragm and intercostal muscles. In obese individuals
it is observed an increased number of ACE2-expressing cells due to
more adipose tissue present (Jia et al., 2020). The overproduction of
proinflammatory cytokines observed in COVID-19 can be especially
harmful for obese patients, since obesity is a condition of systemic low-
grade inflammation. Pneumonia will be present in mild or more ag-
gressive COVID-19, affecting adults or children (WHO, 2020), as a
consequence the lungs will become inflamed and filled with fluid
leading to breathing difficulties causing shortness of breath that can
culminate to ARDS that can be fatal.
The healthy lung has its specific microbiota obtained by micro-
aspiration and inhalation which can be composed by bacteria, molds
and virus. The dynamic of microorganisms that access the lung will be
determined by three factors: immigration, elimination, and the relative
growth rates of its members (Bassis et al., 2015). The prominent genera
in healthy subjects include Prevotella, Veillonella and Streptococcus,
however the Veillonella spp. and Prevotella spp. can also be associated
with the presence of inflammatory cells in the lung (Bassis et al., 2015;
Fanos et al., 2020; Larsen et al., 2014). On the other hand, Pseudomonas
spp. is rare in a healthy lung and Proteobacteria can be found in the
respiratory tract of intubated preterm newborns (Fanos et al., 2020). In
ARDS, the lung microbiota becomes rich in bacteria from the gut, such
as Bacteroidetes and Enterobacteriaceae gut probably because of con-
dition of hyper-permeable gut what facilitates bacterial translocation
through the colon wall and reach the lung (Fanos et al., 2020). Dys-
biosis in gut microbiota has been implicated in several lung diseases,
including allergy, asthma and cystic fibrosis (Anand & Mande, 2018).
Fig. 1 shows the lesions in the pulmonary and intestinal epithelium
resulting of the prevalence of pathogens microorganisms that con-
tribute to an inflammatory environment, in which it may be explored
by SARS-CoV-2 in both microbiota.
There is a possible gut–lung axis which mediates intensive dialogues
between the two organs with both microbial and immune interactions
(Anand & Mande, 2018; Enaud et al., 2020). The microbiota may be
responsible of a crucial role in response to lung bacterial infections, but
the mechanistic basis needs to be deeper investigated (Brown et al.,
2017; Enaud et al., 2020). Brown et al. (2017) begun to decipher this
mechanism, comparing the effect of the microbiota on the innate re-
sponse to pulmonary clearance of Streptococcus pneumoniae (Gram-po-
sitive) and Klebsiella pneumoniae (Gram-negative) using wild-type
C57BL/6 mice. They found that Limosilactobacillus reuteri (formerly
known as Lactobacillus reuteri), Enterococcus faecalis, Lactobacillus cris-
patus, and Clostridium orbiscindens promote resistance to lung infection
through Nod2 (nucleotide-binding oligomerization domain containing
2) and GM-CSF (granulocyte–macrophage colony-stimulating factor)
signaling, which stimulates pathogen killing and clearance by alveolar
macrophages through extracellular signal regulated kinase signaling.
The gut microbiota has a marked influence on metabolic pathways
within alveolar macrophages, which correlates with an altered cellular
responsiveness. Macrophages in microbiota-depleted mice have a di-
minished capacity to phagocytose S. pneumoniae and demonstrate a
reduced cellular responsiveness towards lipoteichoic acid and lipopo-
lysaccharide (Schuijt et al., 2016). Metabolites produced by the gut
microbiota modulate not only the gastro-intestinal immunity, but also
impact distal organs like lung and brain (Anand & Mande, 2018).
Acetate, propionate and butyrate are short chain fatty acids (SCFA)
produced at high concentration by bacteria in the gut and subsequently
released to the bloodstream. Le Poul et al. (2003) identified two specific
receptors of SCFA promoting leukocyte recruitment to the site of in-
fection, as well as their activation. Faced with any infection the immune
system is able to provide tailored responses to different antigens
helping at the defense against respiratory infections. Specialized cells
secrete immunoglobulins/specific antibodies and mediate host defense
by eliminating intracellular pathogens and by killing virus infected cells
(Gil & Guarner, 2004). Fig. 2 shows mechanisms of protection conferred
by beneficial microbes to keep the defenses against viral infection.
Given the very limited therapeutic options available to treat COVID-
19 alternative methods to control the spread of the disease are essential
(Zhang & Liu, 2020). A possible strategy would be to modulate the
microbiome using probiotics, especially Bifidobacteria and Lactobacilli
species (Fanos et al., 2020; Mak et al., 2020). Probiotics may facilitate
the resolution of respiratory symptoms (Anderson et al., 2017; Fanos
et al., 2020), but until this moment there are no scientific evidence that
probiotics administered alone or in combination with prebiotics may
prevent or treat symptoms of COVID-19.
On the other hand, the literature points to the therapeutic potential
of employing probiotics for various disorders of the respiratory system,
as presented at Table 1. There is accumulating evidence supporting the
use of probiotics as preventive measure to reduce AURTI frequency,
duration and the use of medications (Lenoir-Wijnkoop et al., 2016).
Shimizu et al. (2018) evaluated synbiotic supplementation (Bifido-
bacterium breve strain Yakult, L. casei strain Shirota, and galactooligo-
saccharides) on sepsis patients who were mechanically ventilated in the
intensive care unit. They observed a reduction in pneumonia associated
with mechanical ventilation (VAP) in the group supplemented with
symbiotic compared to the placebo. At Cochrane Library a systematic
review on probiotics for preventing VAP was presented (Bo et al., 2014)
indicating some evidence that probiotics may reduce the incidence of
this condition. The probiotics included in this study were L. rhamnosus,
L. plantarum, and Bifidobacterium longum (Bo et al., 2014). Another
Cochrane review on the effect of probiotics for preventing AURTI
evaluated 10 studies and found that compared to placebo, probiotics
may reduce the number of participants with AURTI and may reduce the
number of participants who used antibiotics (Sæterdal et al., 2012).
Lenoir-Wijnkoop et al. (2016) observed a strong potential of probiotic
supplementation to reduce the use of antibiotic and reduction of AURTI
events. According to the model applied on the study it was projected a
higher relative benefit of probiotic consumption among children<10
years old, to individuals living in a community setting, and those not
vaccinated against influenza.
Mechanical ventilation itself poses a risk of co-infections that can
prolong the patient's stay in the hospital and cause new health pro-
blems, such as VAP. Su et al. (2020) carried out a meta-analysis of
randomized clinical trials that compared the use of probiotics in the
prevention of VAP. Among the studies that met the inclusion criteria 6
used single probiotics (L. rhamnosus, L. plantarum 299 or L. casei), 5
used multiple probiotics and 4 a synbiotic formula (detailed in Table 1).
According to the meta-analysis, probiotics appear to reduce the in-
cidence of VAP caused by Pseudomonas aeruginosa (Su et al., 2020).
Virus attachment to a host cell represent an essential step in viral
infection and probiotics may be able to directly bind the virus and
disrupt the infection process (Infusino et al., 2020). Lehtoranta et al.
(2014) evaluated if L. rhamnosus GG and Bifidobacterium animalis ssp
lactis BB-12 were able to decrease nasopharyngeal occurrence of re-
spiratory virus in conscripts. They observed that the probiotics eval-
uated decreased the presence of picornaviruses, proposing that they
would play a role against viruses causing common cold (Lehtoranta
et al., 2014). Luoto et al. (2014) observed reduction of risk of rhinovirus
infection of preterm infants supplemented with galacto-oligosaccharide
and polydextrose mixture and the probiotic L. rhamnosus GG.
The exact mechanism(s) of the antiviral activity of probiotics is not
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completely clear. However, according to Infusino et al. (2020) it can be
summarized as: by reinforcing the mucosal innate immune response, by
reducing intestinal permeability; and by affecting the systemic acquired
immune response through a regulatory and anti-inflammatory effect.
A limitation pointed to some of the cited clinical studies is the lack
of information about the strain(s) of probiotic microorganism(s) in
some of them, which would be useful information, since many of the
health-promoting effects of probiotics are strain-dependent.
6. Conclusion and future perspectives
Facing this pandemic is driving us to find new answers and ways to
face the challenges. In this way, a close relationship between COVID-19
and the intestinal microbiota might explain gut dysfunctions compli-
cations in some patients with more severe clinical course of the disease
(Fanos et al., 2020). However, fermented foods, probiotics, prebiotics,
and synbiotics are capable to modulate the gut and probably at distant
sites such as the respiratory tract. Specific therapeutic strategies can be
proposed, such as the use of probiotic for patients with COVID-related
gastro-intestinal symptoms and in those with mild-moderate systemic
symptoms, trying to prevent cytokine storm (Infusino et al., 2020).
Finally, scientific knowledge must still advance to establish science-
based recommendations of prebiotics and probiotics to prevent or treat
COVID-19.
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